With regard to the role of the blood–brain barrier in brain tumours, we have documented that the tumour-targeting ability of immunocytokine F16–IL2 is comparable in subcutaneous and intracranial mouse xenografts (Figure 4). This evidence concerns the gene IL2 and neoplasm.